Phenotype and engraftment potential of cytokine-mobilized peripheral blood mononuclear cells

Current Opinion in Hematology

Volumn 4, Issue 3, 1997, Pages 176-182

  Mielcarek, Marco ^a   Torok Storb, Beverly ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

BONE MARROW; CELL TRANSPLANTATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL; LEUKAPHERESIS; MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0030873098     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704030-00004     Document Type: Review

References (80)

1. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM: Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989, 74:1905-1914.
2. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992, 339:640-644.
3. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG: Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993, 81:2031-2035.
4. Geissler K, Peschel C, Niederwieser D, Strobl H, Goldschmitt J, Öhler L, Bettelheim P, Kalhs P, Huber C, Lechner K, et al.: Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996, 87:2732-2739.
5. Geissler K, Peschel C, Niederwieser D, Goldschmitt J, Hladik F, Fritz A, Öhler L, Bettelheim P, Huber C, Lechner K, et al.: Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells. Br J Haematol 1995, 91:299-305.
6. Rosenfeld CS, Bolwell B, LeFever A, Taylor R, List A, Fay J, Collins R, Andrews F, Pallansch P, Schuster MW, et al.: Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Bone Marrow Transplant 1996, 17:179-183. This study shows that sequential IL-3 and GM-CSF for mobilization leads to delayed neutrophil recovery. Even though the number of patients is small, this observation illustrates how the mobilization strategy can influence the quality and, therefore, the engraftment potential of the mobilized product.
7. Ghielmini M, Pettengell R, Coutinho LH, Testa N, Crowther D: The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. Br J Haematol 1996, 93:6-12.
8. Pierelli L, Scambia G, Menichella G, D'Onofrio G, Salerno G, Panici PB, Foddai ML, Vittori M, Lai M, Ciarli M, et al.: The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol 1996, 92:287-294.
9. Olivieri A, Offidani M, Cantori I, Ciniero L, Ombrosi L, Masia MC, Brunori M, Montroni M, Leoni P: Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 1995, 16:765-770.
10. Eto T, Takamatsu Y, Harada M, Harada N, Akashi K, Teshima T, Inaba S, Okamura T, Niho Y: Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells. Bone Marrow Transplant 1994, 13:125-129.
11. Laterveer L, Lindley IJD, Hamilton MS, Willemze R, Fibbe WE: Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radio-protective capacity and long-term myelolymphoid repopulating ability. Blood 1995, 85:2269-2275.
12. Haynes A, Hunter A, McQuaker G, Anderson S, Bienz N, Russell NH: Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995, 16:359-363.
13. Yan X-Q, Briddell R, Hartley C, Stoney G, Samal B, McNiece I: Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood 1994, 84:795-799.
14. Tanaka R, Matsudaira T, Aizawa J, Ebihara Y, Muraoka K, Tsuji K, Ikebuchi K, Kodama K, Takaku F, Nakahata T: Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG-CSF) in normal volunteers: dose-effect relationship for filgrastim with the character of mobilized PBPC. Br J Haematol 1996, 92:795-803.
15. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, Lilleby K, Rowley S, Sanders J, Storb R, et al.: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996, 88:2794-2800. Retrospective comparison of 37 allogeneic G-PBMC transplants to matched marrow recipients as historical control subjects. G-PBMC transplantation from HLA-identical donors was associated with faster platelet and neutrophil engraftment, fewer transfusions, and no greater incidence of acute or chronic graft-verus-host disease.
16. Azevedo WM, Aranha FJP, Gouvea JV, Vigorito AC, Marques JFCJ, Eid KAB, Azevedo AM, Souza CA: Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematologic malignancies. Bone Marrow Transplant 1995, 16:647-653.
17. Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al.: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995, 85:1659-1665.
18. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, Hunter A, Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilised by filgrastim (G-CSF). Blood 1995, 85:1666-1672.
19. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655-1658.
20. Hasenclever D, Sextro M: Safety of alloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996, 17:S28-S30.
21. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A, et al.: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357. This is the first randomized trial comparing chemotherapy plus G-CSF-mobilized peripheral blood cell transplants to autologous marrow transplants in lymphoma patients. The number of platelet transfusions, the time-to-platelet and neutrophil recovery, and the hospitalization period was significantly reduced in the peripheral blood stem cell group.
22. Pettengell R, Morgenstern GR, Woll PJ, Chang J, Rowlands M, Young R, Radford JA, Scharffe JH, Testa NG, Crowther D: Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993, 82:3770-3777.
23. Haas R, Moos M, Mohle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996, 17:149-155.
24. Lie AKW, Rawling TP, Bayly JL, To LB: Progenitor cell yield in sequential blood stem cell mobilization in the same patients: insights into chemotherapy dose escalation and combination of haemopoietic growth factor and chemotherapy. Br J Haematol 1996, 95:39-44.
25. Demirer T, Buckner CD, Appelbaum FR, Petersen FB, Rowley S, Weaver CH, Lilleby K, Sanders J, Chauncey T, Storb R, et al.: Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte-colony stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplant 1995, 15:915-922.
26. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:691-697.
27. dlm) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995, 86:2842-2848.
28. Haas R, Witt B, Möhle R, Goldschmidt H, Hohaus S, Fruehauf S, Wannenmacher M, Hunstein W: Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995, 85:3754-3761.
29. Andrews RG, Singer JW, Bernstein ID: Monoclonal antibody 12.8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986, 67:842-845.
30. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Löffler H, Müller-Ruchholtz W, Schmitz N: G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994, 87:609-613.
31. + cells is several-fold greater in G-PBMC compared with immobilized blood and marrow. However, the majority of LTC-IC in G-PBMC does not sustain hematopoiesis for more than 5 weeks and represents, therefore, a more intermediate stage of differentiation between colony-forming units and LTC-IC.
32. + cells infused per kilogram and platelet and neutrophil engraftment kinetics in autologous peripheral blood stem cell transplantation.
33. Breems DA, van Hennik PB, Kusadasi N, Boudewijn A, Cornelissen JJ, Sonneveld P, Ploemacher RE: Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood 1996, 87:5370-5378. Important study that underscores the necessity of combining frequency and quality analysis to compare progenitors in mobilized peripheral blood and marrow. Based on CAFC-and colony-forming unit assays, the authors concluded that the total progenitor cell potency in leukapheresis harvests is threefold higher than in bone marrow.
34. + cell dose in engraftment kinetics. Bone Marrow Transplant 1996, 18:699-703.
35. Serke S, Watts M, Knudsen LM, Kreissig C, Schneider U, Schwella N, Linch D, Johnsen HE: In-vitro clonogenicity of mobilized peripheral blood CD34-expressing cells: inverse correlation to both relative and absolute numbers of CD34-expressing cells. Br J Haematol 1996, 95:234-240.
36. Demirer T, Bensinger WI: Optimization of peripheral blood stem cell collection. Curr Opin Hematol 1995, 2:219-226.
37. Simmons PJ, Zannettino A, Gronthos S, Leavesley D: Potential adhesion mechanisms for localisation of haemopoietic progenitors to bone marrow stroma. Leuk Lymphoma 1994, 12:353-363.
38. To LB, Haylock DN, Dowse T, Simmons JP, Trimboli S, Ashman LK, Juttner CA: A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994, 84:2930-2939.
39. + cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995, 85:3313-3319.
40. Leavesley DI, Oliver JM, Swart BW, Berndt MC, Haylock DN, Simmons PJ: Signals from platelet endothelial cell adhesion molecule enhance the adhesive activity of the very late antigen-4 integrin of human CD34+ hemopoietic progenitor cells. J Immunol 1994, 153:4673-4683.
41. Papayannopoulou T, Nakamoto B: Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci U S A 1993, 90:9374-9378.
42. + peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. Blood 1995, 86:3500-3506.
43. Bender JG, Unverzagt KL, Walker DE, Lee W, Van Epps DE, Smith DH, Stewart CC, To LB: Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991, 77:2591-2596.
44. Fukuda T, Okamura S, Shimoda K, Takamatsu Y, Inaba S, Harada M, Niho Y: Predominance of myeloid antigens in CD34-positive peripheral blood stem cells over those in bone marrow after administration of granulocyte colony-stimulating factor. Br J Haematol 1994, 52:201-206.
45. Inaba T, Shimazaki C, Hirata T, Ashihara E, Okawa K, Oku N, Goto H, Fukita N, Tsuji H, Nakagawa M: Phenotypic differences of CD34-positive stem cells harvested from peripheral blood and bone marrow obtained before and after peripheral blood stem cell collection. Bone Marrow Transplant 1994, 13:527-532.
46. Fritsch G, Stimpfl M, Kurz M, Printz D, Buchinger P, Fischmeister G, Hoecker P, Gadner H: The composition of CD34 subpopulations differs between bone marrow, blood and cord blood. Bone Marrow Transplant 1996, 17:169-178.
47. Mielcarek M, Purton LE, Torok-Storb B: Accessory cell function may be retained in CD34-selected G-CSF mobilized peripheral blood mononuclear cells. Br J Haematol 1996, 93:495-497.
48. +Lin-stem cells from mobilized peripheral blood. Leuk Lymphoma 1996, 22:37-42.
49. + cells may have a lower affinity to the marrow microenvironment and that signals from the marrow microenvironment are required to induce cycling.
50. Craig W, Kay R, Cutler RL, Lansdorp PM: Expression of Thy-1 on human hematopoietic cells. J Exp Med 1993, 177:1331-1342.
51. Podestà M, Piaggio G, Frassoni F, Sessarego M, Benvenuto F, Figari O, Pitto A, Vassallo F, Soracco M, Pollicardo N, et al.: Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myeloid leukemia (CML). Bone Marrow Transplant 1995, 16:549-555.
52. Carella AM, Chimirri F, Podestà M, Pitto A, Piaggio G, Dejana A, Lerma E, Pollicardo N, Vassallo F, Soracco M, et al.: High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1996, 17:201-205.
53. Carella AM, Dejana A, Lerma E, Podesta H, Benvenuto F, Chimirri F, Parodi C, Sessarego M, Prencipe E, Frassoni F: In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996, 95:127-130.
54. Varas F, Bernad A, Bueren JA: Granulocyte colony-stimulating factor mobilizes into peripheral blood the complete clonal repertoire of hematopoietic precursors residing in the bone marrow of mice. Blood 1996, 88:2495-2501. A study in mice that provides evidence that the clonal repertoire in G-PBMC closely reflects the clonal repertoire in the marrow. Therefore, G-CSF does not appear to preferentially mobilize certain subsets of hematopoietic progenitors in these animals.
55. Voso MT, Murea S, Goldschmidt H, Hohaus S, Haas R: High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment. Br J Haematol 1996, 94:759-766.
56. + cells. Blood 1996, 87:949-955.
57. Ponchio L, Conneally E, Eaves C: Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood 1995, 86:3314-3321.
58. Siegen W, Serke S: Cytokine mobilized blood CD34-expressing cells are not cycling [letter]. Bone Marrow Transplant 1996, 17:467-470.
59. Rutella S, Rumi C, Teofili L, Etuk B, Ortu La Barbera E, Leone G: RhG-CSF-mobilized peripheral blood haemopoietic progenitors reside in G0/G1 phase of cell cycle independently of the expression of myeloid antigens [letter]. Br J Haematol 1996, 93:737-738.
60. Roberts AW, Metcalf D: Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. Blood 1995, 86:1600-1605.
61. + hemopoietic progenitors. Blood 1996, 88:1168-1176.
62. Hansen PB, Knudsen H, Gaarsdal E, Jensen L, Ralkiaer E, Johnsen HE: Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability. Bone Marrow Transplant 1995, 16:373-379.
63. Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loufti S, Stock W, Oldenburg D, Unverzagt K, Bender J, et al.: A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant 1995, 16:655-661.
64. Lowenthal RM, Sullivan SA, Parker N, Marsden KA: G-CSF-primed bone marrow cells for autologous transplantation [letter]. Lancet 1996, 347:1125.
65. Weaver CH, Longin K, Buckner CD, Bensinger W: Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994, 13:411-415.
66. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JLM: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 Cytokine production and reduces severity of experimental graft versus host disease. Blood 1995, 86(12):4422-4429. The authors show in a murine transplantation model that the T-helper phenotype of the donor after treatment with G-CSF is polarized toward a type II cytokine response. This demonstrates the potential of functional alterations in accessory cell function after cytokine treatment, which may be relevant for graft-versus-host disease and engraftment.
67. Martin PJ, Kernan NA: T-cell depletion for the prevention of graft-vs-host disease. In Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. Edited by Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K. New York: Marcel Dekker; 1990:371-387.
68. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST: Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994, 84:2436-2446.
69. Mielcarek M, Roecklein BA, Torok-Storb B: CD14+ cells in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells Induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood 1996, 87:574-580. Evidence is presented in an in vitro model that superior accessory cell function in G-PBMC may enhance stromal function post-transplantation which could, in turn, contribute to accelerated early hematopoietic recovery.
70. Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J: Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol 1995, 89:465-472.
71. Purton LE, Lee MY, Torok-Storb B: Normal human peripheral blood mononuclear cells mobilized with granulocyte colony-stimulating factor have increased osteoclastogenic potential compared to nonmobilized blood. Blood 1996, 87:1802-1808.
72. Corringham RE, Ho AD: Rapid and sustained allogeneic transplantation using immunoselected CD34(+)-selected peripheral blood progenitor cells mobilized by recombinant granulocyte-and granulocyte-macrophage colony-stimulating factors [letter]. Blood 1995, 86:2052-2054.
73. Gorin NC, Lopez M, Laporte JP, Quittet P, Lesage S, Lemoine F, Berenson RJ, Isnard F, Grande M, Stachowiak J, et al.: Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995, 85:1647-1654.
74. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994, 84:1421-1426.
75. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, et al.: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994, 12:28-36.
76. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, et al.: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995, 86:390-397.
77. Link H, Arseniev L, Bahre O, Kadar JG, Diedrich H, Poliwoda H: Transplantation of allogeneic CD34+ blood cells. Blood 1996, 87:4903-4909.
78. + blood cells. Blood 1995, 86:2500-2508.
79. Watts MJ, Jones HM, Sullivan AM, Langabeer SE, Jamieson E, Fielding A, Williams C, Berenson RJ, Goldstone AH, Linch DC: Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Haematol 1995, 91:767-772.
80. Mielcarek M, Martin PJ, Torok-Storb B: Suppression of alloantigen-induced T cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997, 89:1629-1634.